Efficacy and safety of donafenib plus transarterial chemoembolization and immunotherapy for hepatocellular carcinoma

doi:10.4251/wjgo.v17.i6.105170

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (215)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-3)

Sum=183

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=23

Jun 15, 2025 (publication date) through Jun 16, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Jun 15, 2025; 17(6): 105170
Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.105170

Open in New Tab Full Size Figure Download Figure

Figure 1 The dynamics of alpha-fetoprotein and des-γ-carboxyprothrombin values at different follow-ups. AFP: Alpha-fetoprotein; DCP: Des-γ-carboxyprothrombin.

Open in New Tab Full Size Figure Download Figure

Figure 2 Percentage changes of tumor size from baseline (summed diameters of target tumors by mRECIST).

Open in New Tab Full Size Figure Download Figure

Figure 3 Kaplan–Meier curve estimate of duration of response, progression-free survival, and overall survival by mRECIST. A: Duration of response; B: Progression-free survival; C: Overall survival. DOR: Duration of response; PFS: Progression-free survival; OS: Overall survival.

Citation: Yang ZH, Liu SN, Chu FY, Yang C, Chen X. Efficacy and safety of donafenib plus transarterial chemoembolization and immunotherapy for hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(6): 105170
URL: https://www.wjgnet.com/1948-5204/full/v17/i6/105170.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i6.105170